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PATHOGENESIS AND IMMUNITY
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A Human STAT1 Gain-of-Function Mutation Impairs CD8ⴙ T
Cell Responses against Gammaherpesvirus 68
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a

Departments of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
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ABSTRACT Autosomal dominant STAT1 mutations in humans have been associated
with chronic mucocutaneous candidiasis (CMC), as well as with increased susceptibility to herpesvirus infections. Prior studies have focused on mucosal and Th17mediated immunity against Candida, but mechanisms of impaired antiviral immunity
have not previously been examined. To begin to explore the mechanisms of STAT1associated immunodeﬁciency against herpesviruses, we generated heterozygous
STAT1 R274W knock-in mice that have a frequently reported STAT1 mutation associated in humans with susceptibility to herpesvirus infections. In primary macrophages
and ﬁbroblasts, we found that STAT1 R274W had no appreciable effect on cellintrinsic immunity against herpes simplex virus 1 (HSV-1) or gammaherpesvirus 68
(␥HV68) infection. However, intraperitoneal inoculation of mice with ␥HV68 was associated with impaired control of infection at day 14 in STAT1 R274W mice compared with that in wild-type (WT) littermate control animals. Infection of STAT1
R274W mice was associated with paradoxically decreased expression of IFNstimulated genes (ISGs) and gamma interferon (IFN-␥), likely secondary to defective
CD4⫹ and CD8⫹ T cell responses, including diminished numbers of antigen-speciﬁc
CD8⫹ T cells. Viral pathogenesis studies in WT and STAT1 R274W mixed bone marrow chimeric mice revealed that the presence of WT leukocytes was sufﬁcient to
limit infection and that antigen-speciﬁc STAT1 R274W CD8⫹ T cell responses were
impaired even in the presence of WT leukocytes. Thus, in addition to regulating
Th17 responses against Candida, a STAT1 gain-of-function mutant impedes antigenspeciﬁc T cell responses against a common gammaherpesvirus in mice.
IMPORTANCE Mechanisms of immunodeﬁciency related to STAT1 gain of function

have not been previously studied in an animal model of viral pathogenesis. Using virological and immunological techniques, we examined the immune response to
␥HV68 in heterozygous mice that have an autosomal dominant mutation in the
STAT1 coiled-coil domain (STAT1 R274W). We observed impaired control of infection,
which was associated with diminished production of gamma interferon (IFN-␥),
fewer effector CD4⫹ and CD8⫹ T cells, and a reduction in the number of antigenspeciﬁc CD8⫹ T cells. These ﬁndings indicate that a STAT1 gain-of-function mutation
limits production of antiviral T cells, likely contributing to immunodeﬁciency against
herpesviruses.
KEYWORDS STAT transcription factors, T cells, herpesviruses, immune deﬁciency,
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A

utosomal dominant STAT1 mutations in humans have been associated with increased susceptibility to infections with Candida as well as with DNA viruses,
including alphaherpesviruses and gammaherpesviruses (1–5). Whereas aberrant mucosal interleukin-17A (IL-17A)-mediated immunity is thought to explain susceptibility to

October 2019 Volume 93 Issue 19 e00307-19

Citation Qian W, Miner CA, Ingle H, Platt DJ,
Baldridge MT, Miner JJ. 2019. A human STAT1
gain-of-function mutation impairs CD8+ T cell
responses against gammaherpesvirus 68.
J Virol 93:e00307-19. https://doi.org/10.1128/
JVI.00307-19.

Journal of Virology

Received 20 February 2019
Accepted 5 July 2019
Accepted manuscript posted online 17 July
2019
Published 12 September 2019

jvi.asm.org 1

Downloaded from https://journals.asm.org/journal/jvi on 17 May 2022 by 128.252.212.229.

Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA

Journal of Virology

Candida (1, 2, 6), mechanisms of impaired antiviral immunity have not previously been
explored, and no animal model of the disease has been described. Since activation of
STAT1 by the type I (␣/␤), type II (␥), and type III () interferon (IFN) receptors leads to
upregulation of antiviral IFN-stimulated genes (ISGs) (7–10), a STAT1 gain-of-function
mutation might be expected to upregulate ISGs and to enhance antiviral immunity.
Thus, it is somewhat counterintuitive that STAT1 gain of function makes humans more
susceptible to viruses.
STAT1 is comprised of N-terminal, coiled-coil, DNA-binding, SH2, and C-terminal
transactivation domains (11). Human mutations in STAT1 have most frequently been
reported in the highly conserved coiled-coil and DNA-binding domains (12–14). The
most commonly reported mutations in the coiled-coil domain are in arginine 274
(R274Q and R274W) (1, 2, 15). Peripheral blood mononuclear cells (PBMCs) from
patients with these mutations have diminished numbers of IL-17-producing T cells,
which may explain susceptibility to Candida (1, 16). Furthermore, overexpression of
R274 mutants in STAT1-deﬁcient cell lines leads to upregulation of an IFN-␥ luciferase
reporter and a corresponding upregulation of ISGs (1, 17). Mutations in R274 also have
been associated with increased phosphorylation of STAT1 upon stimulation with IFN-␥,
IFN-␣, or IL-27 (16–18).
In addition to upregulating expression of antiviral ISGs, STAT1 also regulates adaptive immune responses (19, 20). Therefore, we reasoned that STAT1-associated immunodeﬁciency may reﬂect a combination of innate and adaptive immune defects. To test
this hypothesis, we generated heterozygous STAT1 R274W mice that have an autosomal dominant mutation in the highly conserved STAT1 coiled-coil domain. Here, we
report our discoveries that heterozygous STAT1 R274W mice exhibit impaired antigenspeciﬁc CD8⫹ T cell responses during infection with gammaherpesvirus 68 (␥HV68) and
that this immunological defect is associated with increased viral burden at late but not
early time points. The STAT1 R274W mutation had no impact on ␥HV68 replication in
bone marrow-derived macrophages (BMDMs) or primary mouse embryonic ﬁbroblasts
(MEFs), suggesting that cell-intrinsic control of viral replication remains intact. We
found that the dominant STAT1 R274W mutation impaired both CD4⫹ and CD8⫹ T cell
responses, leading to diminished production of IFN-␥ and a relative decrease in antiviral
ISG expression during acute infection in vivo but not during infection of cultured cells.
Studies in wild-type (WT) and STAT1 R274W mixed bone marrow chimeric mice
revealed that WT leukocytes were sufﬁcient to control infection and that antigenspeciﬁc STAT1 R274W CD8⫹ T cell responses are impaired even in the presence of WT
leukocytes. Thus, the STAT1 R274W gain-of-function mutation impedes antigen-speciﬁc
CD8⫹ T cell responses during gammaherpesvirus infection without signiﬁcantly altering
cell-intrinsic antiviral immunity.
RESULTS
Heterozygous STAT1 R274W mice exhibit impaired control of acute ␥HV68
infection. We used CRISPR/Cas9 to generate knock-in mice with the STAT1 R274W
mutation, which has been associated with increased susceptibility to herpesvirus and
Candida infections in humans (1, 2, 15). The R274W mutation lies within the STAT1
coiled-coil domain, in a region that is highly conserved in mammals (Fig. 1A). Transgenic mice were produced on a C57BL/6J background, backcrossed for 3 generations
prior to experiments, and then continuously backcrossed to wild-type (WT) animals.
Mice were genotyped by Sanger sequencing (Fig. 1B). All of our experiments, including
cell culture studies, were performed using WT littermate mice as controls.
The STAT1 R274W mutation is considered a gain-of-function mutant that limits
dephosphorylation of STAT1 in studies of transfected cells and transformed B cells (16,
17). Previous work indicated that overexpression of human R274 mutants in STAT1deﬁcient cells was associated with a slight hyperresponsiveness to IFN-␥, observed for
both ISG upregulation and STAT1 phosphorylation (16, 17). Therefore, we reasoned that
tissues and cells from heterozygous STAT1 R274W mice would exhibit ISG upregulation.
However, when we examined naive STAT1 R274W mice and cells, we found no
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FIG 1 Generation and initial characterization of heterozygous STAT1 R274W knock-in mice. (A) Schematic functional domain map of STAT1 with corresponding
alignment of the highly conserved coiled-coil domain amino acid sequence, including arginine 274 (R274). (B) Electropherogram of WT and STAT1 R274W
mutant alleles within exon 10. Three nucleotides and one amino acid (R274W) were altered in STAT1 exon 10. (C) Expression of indicated ISGs in the spleens
of 5- to 7-week-old STAT1 R274W mice and WT littermates. Gene expression was measured by reverse transcription-quantitative PCR (qRT-PCR). Relative gene
expression (or fold change) was calculated using the threshold cycle (ΔΔCT) method after normalizing to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Data represent the mean of 10 to 12 spleens per group pooled from two independent experiments. (D and E) Expression levels of CXCL10, IRF1, and IFIT1 in
WT and STAT1 R274W BMDMs (D) and MEFs (E) 6 h after stimulation with 100 ng/ml of recombinant murine IFN-␥. Data represent the mean of three
independent experiments from separate WT and STAT1 R274W primary cell lines. BMDMs (F and G) and MEFs (H and I) were stimulated with 100 ng/ml IFN-␥
for 30 min, and the phosphorylation of STAT1 (p-STAT1) was assessed by Western blotting with antibody to p-STAT1 (Tyr701), using STAT1 and GAPDH as
loading controls. Relative p-STAT1 density was quantiﬁed using ImageJ software and was normalized to GAPDH (n ⫽ 3). (J) Representative ﬂow cytometry
histograms of p-STAT1 levels in BMDMs with and without 100 ng/ml IFN-␥ treatment for 15 or 30 min. (K) Mean ﬂuorescence intensity (MFI) of p-STAT1 in WT
and STAT1 R274W BMDMs with or without 100 ng/ml IFN-␥ treatment for 15 or 30 min. (L) Time course of ISG expression in WT or STAT1 R274W BMDMs at
0, 3, and 6 h after IFN-␥ stimulation. Data in panels J through L represent the mean of n ⫽ 4 to 5 mice per group, pooled from two independent experiments.
All data were analyzed by unpaired t test (P ⬎ 0.1 for all comparisons).
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evidence of ISG upregulation in the spleen, in BMDMs, or in primary MEFs compared
with WT littermate controls (Fig. 1C to E). We also did not observe increased phosphorylation of STAT1 by Western blot of knock-in BMDM or MEF lysates before or after
treatment of cells with 100 ng/ml of IFN-␥ for 30 min (Fig. 1F to I). We also observed no
effect on STAT1 phosphorylation or ISG expression in BMDMs with an IFN-␥ treatment
dose response and time course (Fig. 1J to L). Thus, a heterozygous STAT1 R274W
mutation in mice did not cause spontaneous or IFN-␥-inducible effects on STAT1
phosphorylation or ISG expression in MEFs or macrophages.
Since STAT1 gain-of-function mutations are thought to impact lymphocyte subsets,
including Th17 cells in humans (4), we reasoned that hyperphosphorylation of STAT1 in
response to IFN-␥ may occur only in speciﬁc cell types. Indeed, treatment of cultured
WT and STAT1 R274W splenocytes with IFN-␥ resulted in hyperphosphorylation of
STAT1 in mutant CD8⫹ and CD4⫹ T cells (Fig. 2A to C), but not in B cells or NK cells
compared to WT littermate splenocytes (Fig. 2A, D to E). These results indicate that
although the STAT1 R274W mutation does not alter T cell subsets at baseline in mice,
the mutation may enhance signaling downstream of the IFN-␥ receptor speciﬁcally in
T cells.
Humans with the STAT1 R274W mutation are more vulnerable to gammaherpesvirus
infections, but the mechanism of increased susceptibility to virus infection has not
previously been examined. To deﬁne the role of STAT1 R274W in gammaherpesvirus
infection, we intraperitoneally inoculated 5- to 6-week-old STAT1 R274W and WT
littermate control mice with 106 PFU of ␥HV68, and then measured viral genome copies
October 2019 Volume 93 Issue 19 e00307-19
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FIG 2 Hyperphosphorylation of p-STAT1 in IFN-␥-treated STAT1 R274W T cells. Splenocytes from 6- to 8-week-old STAT1 R274W and WT littermate control mice
were treated with vehicle (medium) or 100 ng/ml IFN-␥ for 15 min followed by ﬂow cytometric analysis of p-STAT1 expression levels in CD8⫹ and CD4⫹ T cells,
B cells, and NK cells. (A) Representative ﬂow cytometry histograms of p-STAT1 in CD8⫹ T cells, CD4⫹ T cells, B cells, and NK cells with and without treatment
with IFN-␥. (B through E) Percent p-STAT1⫹, number of p-STAT1⫹, and MFI of p-STAT1 in CD8⫹ T cells (B), CD4⫹ T cells (C), B220⫹ B cells (D), and NK1.1⫹ NK
cells (E). All data represent the mean of n ⫽ 5 to 9 samples per genotype from three independent experiments and were analyzed by unpaired t test (****,
P ⬍ 0.0001; ***, P ⬍ 0.0005; **, P ⬍ 0.005; *, P ⬍ 0.05).
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by quantitative PCR (qPCR) on days 4, 8, and 14 after infection. On days 4 and 8, the
numbers of ␥HV68 genome copies in the spleens of STAT1 R274W and WT littermate
animals were equivalent (Fig. 3A). However, on day 14 we observed an approximately
5-fold increase in ␥HV68 genome copies in the spleens of STAT1 R274W mice (Fig. 3A).
Lytic (e.g., open reading frame 50 [ORF50], MK3) but not latent (ORF73) genes were
expressed at higher levels on day 14 in the heterozygous STAT1 R274W spleen (Fig. 3B),
suggesting that the increased viral burden reﬂects either reactivation or diminished
control of lytic infection. Indeed, plaque assays demonstrated higher levels of infectious
virus in the spleens of STAT1 R274W mice than in WT control spleens on day 14 (Fig.
3C). More severe infection at late time points was unexpectedly associated with
diminished expression of CXCL10, IRF1, and IFN-␥ in the spleens of STAT1 R274W mice
(CXCL10 ⬃4.2-fold lower, IRF1 ⬃4.5-fold lower, and IFN-␥ ⬃8.6-fold lower in STAT1
R274W; P ⬍ 0.005) (Fig. 3D to F).
Since STAT1 upregulates expression of ISGs downstream of the IFN receptors, we
reasoned that impaired cell-intrinsic antiviral immunity might create a more permissive
environment for viral replication. However, multistep growth curve analysis in BMDMs
and MEFs demonstrated similar ␥HV68 replication in WT and heterozygous STAT1
R274W mutant cells (Fig. 4A and B). Pretreatment of BMDMs with IFN-␥ for 12 h resulted
in similar levels of ␥HV68 replication in WT and STAT1 R274W BMDMs (Fig. 4C).
However, consistent with the notion that STAT1 R274W does indeed have a subtle
gain-of-function effect on ISG expression (17), we detected a slight increase in levels of
Irf1 mRNA in STAT1 R274W cells compared to those in WT controls, as well as a 0.5-fold
increase in CXCL10 expression in ␥HV68-infected MEFs (Fig. 4D and E). These results
indicate that STAT1 R274W-associated effects on ISG expression do not appreciably
October 2019 Volume 93 Issue 19 e00307-19
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FIG 3 Heterozygous STAT1 R274W mice are more susceptible to ␥HV68 and have diminished expression of ISGs
and IFN-␥ during infection. WT and STAT1 R274W mice were intraperitoneally inoculated with 106 PFU of ␥HV68
or PBS control (mock, day 0). Mice were euthanized and the spleen harvested at days 0, 4, 8, and 14 after infection.
(A) Viral genome copies in the splenocytes as measured by qPCR on days 4, 8, and 14 after infection. (B) Expression
of open reading frame 50 (ORF50), ORF73, and MK3 in the spleen as measured by qPCR on day 14 after infection.
(C) Levels of infectious virus in splenocytes as measured by plaque-forming assay on day 14 after infection. (D to
F) Expression levels of CXCL10 (D), IRF1 (E), and IFN-␥ (F) in the spleen as measured by qRT-PCR on days 0, 4, 8,
and 14 after infection. All data represent the mean of n ⫽ 8 to 14 samples per genotype at each time point from
at least two independent experiments and were analyzed by unpaired t test (****, P ⬍ 0.0001; ***, P ⬍ 0.0005; **,
P ⬍ 0.005; *, P ⬍ 0.05).
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impact ␥HV68 replication in our cell culture assays. Similar results were obtained by
examining multistep growth curves and ISG expression after infection of BMDMs and
MEFs with herpes simplex virus 1 (HSV-1) strain 17⫹ (data not shown), indicating
consistent effects of STAT1 R274W for two herpesviruses of distinct subfamilies.
Impaired effector T cell responses in ␥HV68-infected STAT1 R274W mice. Since
the STAT1 R274W mutation has no effect on ␥HV68 and HSV-1 replication in cell
culture, we reasoned that a defect in adaptive immunity might explain increased levels
of ␥HV68 in STAT1 R274W animals. First, we assessed levels of ␥HV68-speciﬁc IgM and
IgG on day 14 after infection, but we observed no differences in levels of virus-speciﬁc
IgM or IgG in STAT1 R274W mice and WT littermates (Fig. 5A and B), suggesting that
the STAT1 gain-of-function mutation does not impact humoral immunity against
␥HV68. However, on day 14 after intraperitoneal inoculation with ␥HV68, but not at
earlier time points, we found that the STAT1 R274W spleens were smaller than WT
littermate control spleens (Fig. 5C). Flow cytometric analysis of splenocytes revealed
that STAT1 R274W mice had a diminished total number of splenic CD45⫹ leukocytes on
day 14 but not at earlier time points after infection (Fig. 5D). The total numbers of B
cells, neutrophils, and monocytes were similar in WT and STAT1 R274W spleens, both
before and after infection (Fig. 5E and data not shown). However, we observed an
⬃2-fold decrease in the total number of CD8⫹ T cells on days 8 and 14 (Fig. 5F), as well
as an ⬃2-fold reduction in CD4⫹ T cells on day 14 (Fig. 5G). These results suggest that
STAT1 R274W limits T cell responses during ␥HV68 infection.
To evaluate CD4⫹ and CD8⫹ T cell subsets, we measured the percentage and
number of T cells that produce IL-17A or IFN-␥ in the spleens of mock- and ␥HV68infected animals. Splenic T cells were also evaluated in the presence and absence of
phorbol 12-myristate 13-acetate (PMA)-ionomycin under all conditions. We observed
no difference prior to infection in the total number of IL-17A-producing CD4⫹ (Th17) or
October 2019 Volume 93 Issue 19 e00307-19
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FIG 4 Multistep ␥HV68 growth curve analysis and gene expression in primary BMDMs and MEFs generated from WT and heterozygous
STAT1 R274W mice. (A and B) BMDMs and MEFs were infected with ␥HV68 at a multiplicity of infection (MOI) of 0.05. The medium
was harvested for quantitation of infectious virus by plaque assay at the indicated time points. (C) BMDMs were pretreated with
medium or IFN-␥ at 100 ng/ml for 12 h before being infected with ␥HV68 at an MOI of 0.05. At the indicated time point after infection,
the virus titer was determined by plaque assay. (D) Relative gene expression levels in BMDMs infected with ␥HV68 at an MOI of 10
for 0, 6, 12, and 24 h, followed by harvesting of cells for RNA isolation and qRT-PCR analysis. (E) Relative gene expression in MEFs
infected with ␥HV68 at an MOI of 10 for 12 h, followed by harvesting of cells for RNA isolation and qRT-PCR analysis. Growth curve
data in panels A through C represent the mean plus or minus standard error of the mean (SEM) of two independent experiments with
3 technical replicates for each growth curve experiment. Data in panel D represent the mean ⫾SEM of 4 or 5 biological replicates
pooled from two independent experiments. Data in panel E represent the mean ⫾SEM of 4 biological replicates pooled from two
independent experiments. Data in panels A, B, and C were analyzed by 2-way analysis of variance (ANOVA). Data in panels D and E
were analyzed by unpaired t test. *, P ⬍ 0.05.
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CD8⫹ (Tc17) cells (Fig. 6A to F) or in the amount of IL-17A produced by IL-17A⫹ CD4⫹
T cells based on mean ﬂuorescence intensity (MFI) (Fig. 6C). In the presence or absence
of PMA-ionomycin, we detected similar numbers of Th17 and Tc17 cells, whether we
examined T cells from mock- or ␥HV68-infected WT and STAT1 R274W mice (Fig. 6A, B
and D, and E). These results suggest that STAT1 R274W does not signiﬁcantly impact
the number of Th17 or Tc17 cells in uninfected mice.
IFN-␥ and T cells are critical for control of ␥HV68 infection (21–28). Upon examination of IFN-␥-expressing T cells, we observed a consistent ⬃2- or 3-fold reduction in the
total number of IFN-␥-producing CD4⫹ and CD8⫹ T cells in infected but not in naive
STAT1 R274W animals compared to that in WT littermate controls (Fig. 6G, H, J, and K).
There was also a subtle increase in the number of IFN-␥-producing naive CD4⫹ T cells
upon stimulation with PMA-ionomycin. After ␥HV68 infection, there was a very small
reduction in the amount of IFN-␥ produced by unstimulated CD4⫹ T cells after ␥HV68
infection, but no difference in the amount of IFN-␥ produced by CD8⫹ T cells in the
presence or absence of stimulation or ␥HV68 infection (Fig. 6I and L). Diminished
numbers of IFN-␥-producing CD4⫹ and CD8⫹ T cells could explain the lower levels of
IFN-␥ and ISG expression in the spleens of ␥HV68-infected STAT1 R274W mice on day
14 after infection (Fig. 3D to F). Additional evaluation of T cell subsets revealed a lower
fraction and number of effector memory CD4⫹ and CD8⫹ T cells by day 8 after
infection, further conﬁrming an effect of STAT1 R274W on effector T cell populations
(Fig. 7A and B).
Next, we measured the number of antigen-speciﬁc CD8⫹ T cells binding the
immunodominant ORF6 tetramer in WT and STAT1 R274W mice on days 0, 4, 8, and 14
after infection. ORF6 tetramer staining revealed that the spleens of STAT1 R274W mice
have a reduced percentage and total number of antigen-speciﬁc CD8⫹ T cells on days
8 and 14 after infection (Fig. 8A to C). Consistent with this ﬁnding, ex vivo restimulation
of splenic T cells with an immunodominant ORF6 peptide also revealed an ⬃2-fold
reduction in the percentage and number of tumor necrosis factor alpha (TNF-␣)- and
IFN-␥-positive CD8⫹ T cells (Fig. 8D to I).
October 2019 Volume 93 Issue 19 e00307-19
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FIG 5 Virus-speciﬁc antibody responses and ﬂow cytometric quantitation of splenic lymphocyte subsets in ␥HV68-infected WT
and STAT1 R274W mice. At ages of 5 to 6 weeks, WT and STAT1 R274W mice were inoculated intraperitoneally with 106 PFU
of ␥HV68 or PBS control (mock, day 0). (A and B) Serum was harvested on day 14 after infection. Virus-speciﬁc IgM (A) and IgG
(B) levels were measured by ELISA. Data represent the mean of n ⫽ 16 biological replicates pooled from two independent
experiments. P ⬎ 0.1 by unpaired t test. (C) Spleen weight prior to isolation of leukocytes. (D to G) Mice were euthanized and
the spleens harvested at days 0, 4, 8, and 14 after infection for ﬂow cytometric analysis. Numbers of CD45⫹ leukocytes (D),
CD19⫹ B cells (E), CD8⫹ T cells (F), and CD4⫹ T cells (G). Data represent the mean of n ⫽ 4 to 8 samples from two independent
experiments. Data were analyzed by unpaired t test. ****, P ⬍ 0.0001; ***, P ⬍ 0.0005; **, P ⬍ 0.005.

Journal of Virology

FIG 6 Flow cytometric analysis of CD4⫹ and CD8⫹ T cell subsets in the spleens of naive and ␥HV68-infected
mice. At age 5 to 6 weeks, WT and STAT1 R274W mice were inoculated intraperitoneally with 106 PFU of
␥HV68 or PBS control (mock). Infected mice were euthanized and splenocytes harvested at day 14 for ﬂow
cytometric analysis. Splenocytes were cultured for 6 h with brefeldin A in the presence or absence (NS) of
PMA-ionomycin (PMA/IOM). (A to C) Percentage (A), number (B), and IL-17A MFI (C) of IL-17A-producing
CD4⫹ T cells from the spleens of mock- and ␥HV68-infected mice. (D to F) Percentage (D), number (E), and
IL-17A MFI (F) of IL-17A-producing CD8⫹ T cells from the spleens of mock- and ␥HV68-infected mice. (G to
I) Percentage (G), number (H), and IFN-␥ MFI (I) of IFN-␥-producing CD4⫹ T cells from the spleens of mockand ␥HV68-infected mice. (J to L) Percentage (J), number (K), and IFN-␥ MFI (L) of IFN-␥-producing CD8⫹
T cells from the spleens of mock- and ␥HV68-infected mice. Data represent the mean of n ⫽ 14 to 16
samples from two independent experiments. Results were analyzed by unpaired t test. ****, P ⬍ 0.0001; **,
P ⬍ 0.005; *, P ⬍ 0.05.

Because of the antigen-speciﬁc CD8⫹ T cell defects that we observed in STAT1
R274W animals, we reasoned that mixed bone marrow chimeric mice with both WT and
STAT1 R274W leukocytes would allow us to more precisely deﬁne the relative phenotypes and functions of WT and STAT1 R274W CD8⫹ T cells during infection. We
intravenously injected equal numbers of congenic CD45.1⫹ WT and CD45.2⫹ WT or
STAT1 R274W bone marrow cells into lethally irradiated WT and STAT1 R274W recipient
mice (Fig. 9A). This resulted in generation of two groups, WT/WT and WT/STAT1 R274W
October 2019 Volume 93 Issue 19 e00307-19
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FIG 7 Flow cytometric quantitation of naive (TN), effector memory (TEM), and central memory (TCM) CD8⫹
and CD4⫹ T cell subsets in the spleens of naive and ␥HV68-infected mice. WT and STAT1 R274W mice
were inoculated intraperitoneally at age 5 to 6 weeks with 106 PFU of ␥HV68 or PBS control (mock, day
0). Infected mice were euthanized and splenocytes harvested at days 0, 4, 8, and 14 for ﬂow cytometric
analysis of CD8⫹ and CD4⫹ naive (CD44loCD62Lhi) T cells, effector memory (CD44hiCD62Llo) T cells, and
central memory (CD44hiCD62Lhi) T cells. (A and B) Percentage and numbers of naive (TN), effector
memory (TEM), and central memory (TCM) CD8⫹ (A) and CD4⫹ (B) T cell subsets at the indicated time
points. Data represent the mean ⫾SEM of n ⫽ 4 to 8 mice per genotype at each time point. Data were
analyzed by 2-way ANOVA. ****, P ⬍ 0.0001; ***, P ⬍ 0.0005; **, P ⬍ 0.005; *, P ⬍ 0.05.

mixed bone marrow chimeras. Six weeks later, we conﬁrmed reconstitution of peripheral blood leukocytes, including similar percentages of CD45.1⫹ and CD45.2⫹ cells in
recipient animals (data not shown). Fourteen days after intraperitoneal inoculation with
106 PFU of ␥HV68, we observed no difference in levels of viral DNA or infectious virus
between the spleens of WT/WT and WT/STAT1 R274W recipient mice (Fig. 9B and C).
This suggests that the presence of WT leukocytes is sufﬁcient to control ␥HV68
infection, even when STAT1 R274W leukocytes and radioresistant recipient cells are also
present. Evaluation of leukocyte subsets revealed a slightly higher percentage and
number of CD45.2 leukocytes, including B cells, in both groups of mixed bone marrow
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FIG 8 The STAT1 R274W mutation impairs antigen-speciﬁc CD8⫹ T cell responses during ␥HV68
infection. WT and STAT1 R274W mice were inoculated intraperitoneally at age 5 to 6 weeks with 106 PFU
of ␥HV68 or PBS control (mock, day 0). Infected mice were euthanized and splenocytes harvested at days
0, 4, 8, and 14 for ﬂow cytometric analysis. (A) Representative dot plots of antigen-speciﬁc CD8⫹ T cells
quantitated by ﬂow cytometric analysis following ORF6 tetramer staining. (B and C) Quantitation of the
percentage (B) and number (C) of ORF6 tetramer⫹ CD8⫹ T cells by ﬂow cytometry on days 0, 4, 8, and
14 after infection. (D and E) Representative dot plots of TNF-␣- (D) and IFN-␥-expressing (E) CD8⫹ T cells
at day 14 were quantitated by ﬂow cytometric analysis after restimulation with or without (NS) the
immunodominant ORF6 peptide. (F-G) Percentage (F) and number (G) of TNF-␣-expressing CD8⫹ T cells.
(H-I) Percentage (H) and number (I) of IFN-␥-expressing CD8⫹ T cells. Data represent the mean of n ⫽ 4
to 8 mice per genotype pooled from two independent experiments. Results were analyzed by unpaired
t test. ****, P ⬍ 0.0001; ***, P ⬍ 0.0005; **, P ⬍ 0.005; *, P ⬍ 0.05.
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chimeras (Fig. 9D to F). This was anticipated, given the fact that radioresistant cells in
recipient animals also express CD45.2⫹. Among CD4⫹ and CD8⫹ T cells, we observed
only a slight increase in CD45.2⫹/CD4⫹ T cells in WT/WT chimeras, and no difference
in the total number of CD8⫹ T cells in either group of chimeras (Fig. 9G and H).
However, evaluation of antigen-speciﬁc CD8⫹ T cells on day 14 after infection revealed
an ⬃2.5-fold reduction in both the percentage and number of STAT1 R274Wexpressing ORF6 tetramer⫹ CD8⫹ T cells (Fig. 9I to K). No difference was observed in the
percentage or number of antigen-speciﬁc CD8⫹ T cells in WT/WT mixed chimeras or in
WT CD45.1⫹ CD8⫹ cells in STAT1 R274W recipient animals (Fig. 9I to K). These results
demonstrate that STAT1 R274W-associated impairment of antigen-speciﬁc CD8⫹ T cell
responses can occur even in the presence of WT leukocytes. Impaired production of
antigen-speciﬁc CD8⫹ T cells might be a consequence of cell-intrinsic antiproliferative
effects of STAT1 (29, 30).
Collectively, our ﬁndings demonstrate that STAT1 R274W impairs production of
CD4⫹ and CD8⫹ effector T cells during ␥HV68 infection, without substantially affecting
cell-intrinsic control of ␥HV68 replication in target cells, including BMDMs and ﬁbroblasts. Because IFN-␥ signaling, as well as antigen-speciﬁc T cells, plays a major role in
controlling ␥HV68 infection in mice (24–27), the impaired production of antiviral T cells
likely contributes to immunodeﬁciency caused by STAT1 gain of function.
DISCUSSION
Since STAT1 gain-of-function mutations cause chronic mucocutaneous candidiasis
in humans, prior work in human cells has focused on Th17 responses that promote
antifungal immunity. But STAT1 mutations are also associated with susceptibility to
viruses (4), and the mechanism of antiviral immunodeﬁciency was not previously
explored. Using a STAT1 R274W knock-in mouse model, we found that heterozygous
STAT1 mutant mice exhibited impaired control of gammaherpesvirus infection in vivo.
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FIG 9 Impaired STAT1 R274W antigen-speciﬁc CD8⫹ T cell responses after ␥HV68 infection of WT and STAT1 R274W mixed bone marrow chimeric mice. (A to
K) STAT1 R274W and WT littermate animals were lethally irradiated followed by intravenous injection of a 1:1 mixture of CD45.1 WT bone marrow cells and
either CD45.2 WT or STAT1 R274W bone marrow cells. This resulted in generation of WT/WT chimeras and WT/STAT1 R274W chimeras. Six weeks later, after
reconstitution of similar numbers of circulating leukocytes, mice were intraperitoneally inoculated with 106 PFU of ␥HV68 and then euthanized 14 days after
infection for virological and immunological analysis (A). (B) Viral DNA levels in the spleen as measured by qPCR. (C) Infectious virus levels in the spleens of mixed
bone marrow chimeric mice as measured by plaque assay. The dashed line indicates the limit of detection of the assay at 10 PFU/g of tissue. (D and E) Flow
cytometric analysis of the percentage (D) and number (E) of CD45.1⫹ and CD45.2⫹ leukocytes in the spleens of mixed bone marrow chimeric mice. (F to H)
Numbers of CD19⫹ B cells, CD4⫹ T cells, and CD8⫹ T cells in the spleen after infection as measured by ﬂow cytometry. (I) Representative dot plots of ORF6
tetramer⫹ CD8⫹ T cells in mixed bone marrow chimeric mice. (J and K) The percentage (J) and number (K) of ORF6 tetramer⫹ CD8⫹ T cells in mixed bone
marrow chimeric mice. Data represent the mean of n ⫽ 8 to 9 chimeric mice per group pooled from two independent experiments. Results were analyzed by
unpaired t test. ****, P ⬍ 0.0001; ***, P ⬍ 0.0005; **, P ⬍ 0.005.
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Although STAT1 R274W led to a slight upregulation of ISGs during infection with ␥HV68
in cell culture, viral replication was not impacted in vitro (Fig. 4). Furthermore, we
observed lower IFN-␥ production and ISG expression in vivo despite increased viral
burden at late time points in STAT1 R274W mice (Fig. 3). These results corresponded
with diminished numbers of infection-associated effector CD4⫹ and CD8⫹ T cells,
including antigen-speciﬁc CD8⫹ T cells. We also found markedly diminished levels of
IFN-␥ in the spleen only at later time points (days 8 and 14), when antigen-speciﬁc T cell
responses occur. Although we are not able to conclude deﬁnitively whether these
adaptive immune defects are responsible for STAT1 R274W-associated susceptibility to
viral infection, our studies of mixed bone marrow chimeric mice support the conclusion
that STAT1 R274W impairs control of infection because of effects on antigen-speciﬁc
CD8⫹ T cells. Furthermore, CD8⫹ T cells were previously demonstrated to play a major
role in controlling ␥HV68 infection (21–28).
STAT1 integrates signals downstream of multiple antiviral cytokine receptors, including the type I, II, and III IFN receptors (10). Indeed, mice lacking IFN-␥, the IFN-␥
receptor, or STAT1 are highly vulnerable to gammaherpesvirus infection (27). Although
human STAT1 mutations have previously been studied extensively in cell culture (1),
mechanisms of human STAT1 R274W-associated immunodeﬁciency have not previously been deﬁned in an animal model of the disease. Cell culture and ﬂow cytometric
analysis of human PBMCs previously revealed that STAT1 mutations are associated with
increased inducible expression of ISGs (1, 31). This prior work has provided key insight
into mechanisms of STAT1-associated immunodeﬁciency in humans and transfected
cells, but with some limitations, since the assays utilize overexpression systems, cells
that lack endogenous STAT1 (1, 17), Epstein-Barr virus (EBV)-transformed B cells (1, 16,
17), or patient PBMCs that may have been latently infected (17, 31). Thus, although our
work has substantial limitations related to potential species-speciﬁc effects of STAT1,
the STAT1 R274W knock-in mouse model has allowed us to perform an immunological
evaluation of STAT1 gain of function under isogenic conditions, without overexpression, and without EBV-mediated transformation of primary cells.
Since the STAT1 R274W mutation is regarded as gain of function (1, 2), we initially
anticipated that we would detect increased basal and inducible upregulation of ISGs in
STAT1 R274W BMDMs and MEFs. However, we found that STAT1 R274W was associated
with only a mild upregulation of ISGs in cultured MEFs and BMDMs, and this was not
enough to impact ␥HV68 replication (Fig. 4). However, treatment of cultured splenocytes with IFN-␥ resulted in T cell-speciﬁc hyperphosphorylation of STAT1 (Fig. 2). This
suggests that the STAT1 R274W mutation exerts T cell-speciﬁc effects on STAT1
signaling. Although we observed no impact of the mutation on ␥HV68 replication in
primary MEFs or macrophages, we cannot exclude the possibility that ␥HV68 may
replicate more efﬁciently in STAT1 R274W B cells. However, the results of our ␥HV68
pathogenesis studies in mixed bone marrow chimeric mice argue against this possibility.
In humans, STAT1 gain of function is thought to cause vulnerability to mucocutaneous candidiasis via its effects on Th17 cells (1, 2, 6), but it is not known whether
defects in Th17-mediated immunity can create susceptibility to gammaherpesvirus
infection. We discovered that STAT1 gain of function impairs CD4⫹ and CD8⫹ T cell
responses (Fig. 5), including antigen-speciﬁc CD8⫹ T cell responses against ␥HV68 (Fig.
8). Antiviral CD4⫹ and CD8⫹ T cells are already known to play a major role in controlling
␥HV68 infection (21–28). However, it is not known whether a similar defect in antigenspeciﬁc T cell responses may occur during virus infection in humans, so this could be
a topic of future study. Whether these animals will provide a suitable model for the
study of mucocutaneous candidiasis also remains to be determined.
Our mixed bone marrow chimeric mouse studies support the conclusion that STAT1
R274W creates immunodeﬁciency because of its effects on antigen-speciﬁc CD8⫹ T cell
responses. Impaired T cell responses may be a consequence of cell-intrinsic factors,
since we observed an ⬃2.5-fold reduction in antigen-speciﬁc STAT1 R274W CD8⫹ T
cells compared to WT T cells in mixed bone marrow chimeric mice (Fig. 9I to K).
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However, our results do not exclude combined cell-intrinsic and extrinsic effects on T
cell responses in STAT1 R274W mice. Prior studies of human cells revealed that STAT1
gain-of-function mutant macrophages may express higher levels of PD-L1 (32), which
limits Th17 cell differentiation. Thus, one possibility is that upregulation of PD-L1 or
other inhibitory proteins may dampen T cell responses against viruses, in addition to
impairing Th17-mediated immunity against Candida. However, contributions of STAT1
R274W-associated cell-extrinsic factors are likely insufﬁcient to impede antigen-speciﬁc
CD8⫹ T cell responses, since numbers of tetramer-positive WT CD8⫹ T cells were not
signiﬁcantly different in WT and STAT1 R274W recipient animals in our studies of mixed
bone marrow chimeric mice.
Although the majority of virus infections in STAT1 gain-of-function patients were
herpesvirus infections (4), the reason STAT1 gain of function preferentially creates
immunodeﬁciency against herpesviruses remains to be fully deﬁned. In the future, cell
type-speciﬁc STAT1 mutant mice will be useful to determine how STAT1 R274W impairs
antiviral T cells. Finally, given our discovery that the STAT1 coiled-coil domain impacts
T cells, our ﬁndings suggest that small molecular targeting of the STAT1 coiled-coil
domain might be worth future exploration as a potential therapy, either to promote
antiviral or antitumoral immunity with agonists or to limit T cell-mediated autoimmunity using antagonists.

Design. The goal of this project was to deﬁne mechanisms of immunodeﬁciency in STAT1 R274W
mice during gammaherpesvirus infection. We conducted a power analysis for Institutional Animal Care
and Use Committee-approved studies in order to predetermine the number of animals needed per
experimental group. We used WT littermate mice as control animals in all studies of STAT1 R274W mice.
No outliers were excluded from analyses. At least two or three independent in vivo experiments were
performed to replicate ﬁndings. The number of biological replicates for each experiment is listed in the
legends to Fig. 1 to 9.
Study approvals. All protocols for animal studies were approved by the Institutional Animal Care
and Use Committees at the Washington University School of Medicine (assurance no. A-3381-01).
Generation of STAT1 R274W knock-in mice. Mice heterozygous for the STAT1 R274W mutation
were generated by and obtained from Applied StemCell, Inc. Brieﬂy, to generate STAT1 R274W knock-in
mice, a single guide RNA (sgRNA; 5=-CTGCTGACGGATCTGCTGCA-3=) was designed to target STAT1
arginine 274 in exon 10. A single-stranded oligonucleotide donor (ssODN) encoding the amino acid
substitution (R274W) with homology arms was synthesized (5=-GCATGTGGAGATTCTGTGACTCTCTCATC
TAGTGTGTTTTGGGACTGTTGTTCATGGAGACCCCATGTCCTGTACCCTCCCAGGTTCACCATTGTTGCAGAGACa
CTGCAGCAGATCtGgCAGCAGCTTAAAAAGCTGGAGGAGTTGGAACAGAAATTCACCTATGAGCCCGACCCTAT
TACAAAAAACAAGCAGGTGTT-3=; mutant nucleotides are indicated by underlined lowercase). C57BL/6J
mice were superovulated and mated with C57BL/6J males. Single-cell embryos were isolated and
injected with a combination of Cas9, guide RNA (gRNA), and ssODN. Modiﬁed embryos were transferred
into pseudopregnant female recipient mice. One founder mouse was received and backcrossed to WT
C57BL/6J animals for three generations and continued to be backcrossed in perpetuity since all studies
involved heterozygous animals. WT littermate control mice were used for all experiments. A serendipitous synonymous mutation was identiﬁed in the third nucleotide of the codon for isoleucine 273. The
synonymous mutation, which did not alter the amino acid sequence may have limited recutting of the
mutant allele by Cas9.
Mice, viruses, and cells. Mice were housed in speciﬁc pathogen-free mouse facilities at the
Washington University School of Medicine. Experiments were performed on 5- to 6-week-old heterozygous STAT1 R274W mice, and WT littermates were used as controls. ␥HV68 strain WUMS (ATCC VR1465)
was purchased from ATCC and used for all experiments. Virus was passaged and the titer was determined
by infectious plaque assay in NIH 3T12 cells (ATCC CCL-164). HSV-1 strain 17⫹ (33), provided by the T.
Margolis laboratory (Washington University, Saint Louis, MO), was passaged in Vero cells. 3T12 cells and
mouse embryonic ﬁbroblasts (MEFs) were maintained in Dulbecco modiﬁed Eagle medium (DMEM)
supplemented with 5% and 10% fetal bovine serum (FBS), respectively, along with 1% of L-glutamine,
HEPES, and penicillin-streptomycin at 37°C in 5% CO2. MEFs from STAT1 R274W and WT littermate
embryos on embryonic day 14.5 (E14.5) were obtained as previously described (34). Bone marrowderived macrophages (BMDMs) from femurs and tibias of 7-week-old STAT1 R274W and WT littermate
mice were generated by culturing bone marrow cells for 7 days in BMDM media (DMEM with 10% FBS,
1% penicillin-streptomycin, 1% L-glutamine, 1% HEPES, and 40 ng/ml of mouse macrophage colonystimulating factor [M-CSF]).
Antibodies and other reagents. Antibodies used for ﬂow cytometry included CD45 (clone name
30-F11), CD45.1 (A20), CD45.2 (104), B220 (RA3-6B2), NK1.1 (PK136), CD11b (M1/70), F4/80 (BM8), CD19
(6D5), CD3 (145-2C11), CD4 (GK1.5), CD8␣ (53-6.7), CD8␤ (YTS156.7.7), CD44 (IM7), CD62L (MEL-14),
IL-17A (TC11-18H10.1), and TNF-␣ (MP6-XT22) from BioLegend. Other antibodies utilized in ﬂow cytometry included CD45 (30-F11; BD Biosciences), phospho-STAT1 (p-STAT1) (4a; BD), IFN-␥ (XMG1.2; eBioOctober 2019 Volume 93 Issue 19 e00307-19
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science), and FcBlock (2.4G2; BD). STAT1 antibody (no. 9172), phospho-STAT1 (Tyr701) rabbit monoclonal
antibody (MAb) (no. 7649), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) rabbit MAb (no.
2118) were obtained from Cell Signaling Technology (CST). Other reagents were recombinant murine
IFN-␥ (315-05; PeproTech), mouse macrophage colony-stimulating factor (M-CSF) (300-25; PeproTech),
phorbol 12-myristate 13-acetate (PMA) (P8139; Sigma), ionomycin (IOM) (I0634; Sigma), and brefeldin A
(eBioscience).
Infections and tissue harvests. Five- to 6-week-old STAT1 R274W heterozygous mice and WT
littermates were inoculated intraperitoneally with 106 PFU of ␥HV68 in 100 l of phosphate-buffered
saline (PBS). Mice were euthanized under anesthesia at the indicated time points. Blood samples were
collected via cheek pouch puncture into 1.5-ml tubes. For titration, mouse splenocytes or spleens were
harvested and stored at ⫺80°C prior to disruption. For ﬂow cytometry experiments, harvested mouse
spleens were stored in ﬂuorescence-activated cell sorter (FACS) buffer (PBS with 4% FBS) or T cell
medium (RPMI with 10% FBS and 0.1% 2-mercaptoethanol) for further processing.
Viral burden analysis. Spleens were weighed and homogenized in 200 l of PBS using zirconia
beads and a MagNA Lyser (Roche Life Sciences). Total DNA was isolated from 15 l of homogenate using
the DNeasy blood and tissue kit (catalog no. 69504; Qiagen). ␥HV68 genome copies were quantitated
using an established qPCR assay to detect ORF8, as described previously (28). A standard curve was used
for absolute quantitation of genome copy numbers, also as previously described (28). Infectious ␥HV68
in spleens was analyzed by plaque assay as previously described (35, 36). In brief, 3T12 cells were seeded
in 12-well plates 1 day prior to infection, and then four 10-fold serial dilutions of spleen homogenates
were plated on 3T12 monolayers. After 2 h adsorption, cells were overlaid with 2 ml of 2% methylcellulose in minimum essential medium (MEM) supplemented with 5% FBS. Plates were ﬁxed on day 6 with
4% paraformaldehyde (PFA) and stained with 0.5% crystal violet solution containing 20% methanol.
Plates were air dried on paper towels for 24 h, followed by counting of PFU. The limit of detection was
10 PFU per gram of tissue.
Immunoblot analysis of STAT1 phosphorylation. Mouse IFN-␥-treated BMDMs and MEFs were
lysed in radioimmunoprecipitation assay (RIPA) buffer (catalog no. 9806S; CST) supplemented with a
protease inhibitor (catalog no. 78430; Thermo Fisher) and phosphatase inhibitor (catalog no. 88667;
Thermo Fisher). An equal amount of protein was loaded and separated on 10% SDS-PAGE gels (Bio-Rad),
and then transferred to polyvinylidene ﬂuoride membranes (EMD Millipore). Primary antibodies against
phosphor-STAT1 (Tyr701), STAT1, and GAPDH were stained and detected by the use of horseradishperoxidase-conjugated secondary anti-rabbit antibody (catalog no. 31460; Invitrogen). All blots were
performed using Pierce ECL substrate (Thermo Fisher Scientiﬁc) and scanned with a ChemiDoc touch
imaging system (Bio-Rad).
Viral growth curves. BMDMs and MEFs were seeded in triplicate in 24-well plates, and cells were
infected with ␥HV68 or HSV-1 at a multiplicity of infection (MOI) of 0.05 and 0.01, respectively. For ␥HV68
growth curves, supernatant was collected at 1, 24, 48, 72, 96, and 120 h after infection and then
determined by plaque assay. In some experiments, cells were pretreated with IFN-␥ as described in the
legend to Fig. 4. For HSV-1 growth curve analysis, supernatant was collected at 1, 12, 24, 48, 72, and 96 h
after infection, and Vero cells were infected with serial dilution of samples by incubation for 2 h and then
overlaid with 2% methylcellulose in MEM supplemented with 1% FBS. After 3 to 4 days of incubation,
monolayers were ﬁxed in PFA and stained with 0.5% crystal violet solution, and then viral plaques were
counted.
Measurement of gene expression by reverse transcription-quantitative PCR (qRT-PCR). Total
RNA from infected or uninfected spleen homogenates and from IFN-␥-stimulated, unstimulated, or
infected BMDMs and MEFs was extracted using the RNeasy kit (Qiagen) according to the manufacturer’s
instructions. qRT-PCR was performed using a TaqMan RNA-to-CT 1-step kit (Applied Biosystems) according to the manufacturer’s instructions. Results were calculated using the threshold cycle (ΔΔCT) method,
normalizing to GAPDH. Primers were obtained from Integrated Device Technology, Inc. (IDT).
Virus-speciﬁc antibody ELISAs. ␥HV68-speciﬁc IgG and IgM enzyme-linked immunosorbent assays
(ELISAs) were performed as described previously (28). Nunc MaxiSorp ﬂat-bottom 96-well plates were
coated with ␥HV68 for 12 h, followed by blocking with 1% bovine serum albumin for 1 h at room
temperature. Wells were washed three times with wash buffer (PBS-0.1% Tween) before adding the
serum samples. After 2 h of incubation, the wells were washed and incubated with horseradish
peroxidase-conjugated IgG and IgM antibodies for 2 h before adding the tetramethylbenzidine (TMB)
ELISA substrate (Thermo Fisher, USA). Reactions were stopped by adding 2 normal H2SO4. Plates were
analyzed on a BioTek Synergy 2 multidetection microplate reader (BioTek) using Gen5 software (BioTek).
Serially diluted mouse IgG (Sigma-Aldrich, USA) or IgM (EMD Millipore) were used for the standard curve.
Flow cytometry and intracellular cytokine stimulation. Spleens were mashed and ﬁltered through
a 70m cell strainer to make single cell suspensions. For analysis of surface markers, cells were stained
ex vivo for 30 min on ice in FACS buffer using antibodies to CD45, CD19, CD3, CD4, CD8␣, CD44, and
CD62L. For intracellular cytokine quantiﬁcation, splenocytes were stimulated for 6 h at 37°C with
50 ng/ml PMA and 1 g/ml IOM in the presence of brefeldin A. Following the 6-h stimulation, cells were
stained as above with CD45, CD19, CD4, and CD8␣, then cells were washed and ﬁxed, permeabilized
(00-5123-43; eBioscience), and stained with IL-17A and IFN-␥ antibodies. Samples were run on a BD
FACSCanto instrument, and data were analyzed using Cytobank and FlowJo software. For phosphoSTAT1 staining, BMDMs or splenocytes were stimulated for the indicated times with 100 ng/ml of IFN-␥.
Subsequently, cells were ﬁxed with 2% PFA for 10 min at room temperature, permeabilized with ice-cold
methanol for 15 min on ice, and stained with p-STAT1, along with CD45, CD11b, and F4/80 in BMDMs
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or with CD45, B220, CD3, CD4, CD8, and NK1.1 in splenocytes for 1 h on ice. Sampling was performed on
an Attune NxT ﬂow cytometer and data analyzed using FlowJo software.
Measurement of antigen-speciﬁc CD8ⴙ T cell responses. We utilized tetramers binding to T cell
receptors speciﬁc to the ORF6-derived peptide AGPHNDMEI of ␥HV68. Tetramers were generated by the
Andrew and Jane M. Bursky Center for Human Immunology and Immunotherapy (CHiiPs) and subsequently validated by FACS and utilized for staining of antigen-speciﬁc T cells (28). Staining of intracellular
IFN-␥ and TNF-␣ was also performed as previously described (28), following 6 h of ex vivo restimulation
with the ORF6 peptide in the presence of brefeldin A. Splenocytes were washed and stained to
antibodies against CD45, CD19, CD4, CD8␣, CD8␤, TNF-␣, and IFN-␥. Results were obtained by ﬂow
cytometry and analyzed using Cytobank.
Mixed bone marrow chimeric mouse studies. Four- to 5-week-old and 5- to 6-week-old STAT1
R274W and WT littermate recipient mice were lethally irradiated, followed by intravenous injection with
a 1:1 mixture of CD45.1 WT bone marrow cells and either CD45.2 WT or STAT1 R274W bone marrow cells
in 100 l of PBS. This resulted in generation of WT/WT chimeras and WT/STAT1 R274W chimeras. Six
weeks later, after conﬁrming reconstitution of circulating donor leukocytes by FACS, mice were intraperitoneally inoculated with 106 PFU of ␥HV68 and then euthanized 14 days after infection for virological
and immunological analysis.
Statistical analysis. All data were analyzed using GraphPad Prism software, and statistical analyses
were performed as described in the legends to Fig. 1 to 9.
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